News

UK-based Monument Therapeutics has joined forces with the Foundation for the National Institutes of Health (FNIH), US, to ...
Monument Therapeutics partners with FNIH to advance MT1988, a promising treatment for cognitive impairment in schizophrenia, ...
Cambridge Cognition said on Tuesday that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to trial a new treatment for ...
(Alliance News) - Cambridge Cognition Holdings PLC on Tuesday said Monument Therapeutics, in which it holds a 20% stake, has partnered up on the development of a novel treatment for cognitive ...
Monument Therapeutics, a stratified medicine company, today announced a partnership with the Foundation for the National ...